Compare Jones Lang LaSalle Inc (JLL) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Jones Lang LaSalle Inc vs Regeneron Pharmaceuticals Inc — how do they compare? Jones Lang LaSalle Inc trades at $361.02 (market cap $16.72B), while Regeneron Pharmaceuticals Inc trades at $796.38 (market cap $82.06B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 4.9× Jones Lang LaSalle Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.47% dividend while Jones Lang LaSalle Inc pays none. Which is the better fit depends on your goals.
| JLL | REGN | |
|---|---|---|
Market Cap | $16.72B | $82.06B |
Sector | Real Estate | Health |
52-Week High | $373.24 | $812.27 |
52-Week Low | $280.16 | $555.51 |
Enterprise Value | $19.48B | $76.77B |
Dividend Yield | — | 0.47% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Jones Lang LaSalle Inc
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $70 billion for clients across diverse public and private real estate strategies.
Read more on JLL →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
